Stock Alert: Inovio Rises 4%

By RTTNews Staff Write  ✉   | Published:

Shares of Inovio Pharmaceuticals, Inc. (INO) are climbing more than 4% Monday morning after the company said it has received clearance from the FDA to start Phase 2/3 study of its Covid-19 vaccine candidate, INO-4800.

In September, the FDA had sought for additional information about the phase 2/3 study and has been put on hold.

The phase 2/3 study dubbed INNOVATE, will be funded by the U.S. Department of Defense, the company said.

INO is currently trading at $11.69. It has traded in the range of $2.20- $33.79 in the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Previous Story
Next Story
Editors Pick
Tyson Foods Q4 Adj. EPS Tops View; Guides FY21 Sales Below View
Meat processor Tyson Foods Inc. reported Monday a profit for the fourth quarter that increased from last year, reflecting sales growth at most of its operating segments. Adjusted earnings per share topped analysts' expectations. The company also initiated sales guidance for the full-year 2021 and boosted quarterly dividend 6 percent.
Moderna Says COVID-19 Vaccine Candidate More Than 94% Effective
Moderna, Inc. said Monday that preliminary data from the Phase 3 study of its coronavirus vaccine candidate, mRNA-1273, has shown the vaccine to be more than 94 percent effective. The Phase 3 study, known as the COVE study, enrolled more than 30,000 participants in the U.S. Following the news, the company's stock jumped more than 15 percent in pre-market to trade at $103.
InvoSpa Recalls Heated Blankets Sold Exclusively At Amazon.com
Shaft Innovations UK Ltd. d/b/a InvoSpa recalled about 7,050 units of Electric Throw Heated Blankets for potential fire and burn hazards, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the heated blankets can overheat due to a problem in the controller and do not comply with federal safety requirements, thus posing a risk of fire and burn injury.